These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26766804)

  • 61. 'Post-finasteride syndrome': what to tell our female patients?
    Mervis JS; Borda LJ; Miteva M
    Br J Dermatol; 2018 Sep; 179(3):785-786. PubMed ID: 29624646
    [No Abstract]   [Full Text] [Related]  

  • 62. An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia.
    Chiriacò G; Cauci S; Mazzon G; Trombetta C
    Andrology; 2016 Mar; 4(2):245-50. PubMed ID: 26763726
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System.
    Gupta AK; Carviel J; Gupta MA; Shear NH
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1373-1376. PubMed ID: 29194783
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia.
    Tosti A; Pazzaglia M; Soli M; Rossi A; Rebora A; Atzori L; Barbareschi M; Benci M; Voudouris S; Vena GA
    Arch Dermatol; 2004 Jul; 140(7):857-8. PubMed ID: 15262698
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Finasteride-induced secondary infertility associated with sperm DNA damage.
    Tu HY; Zini A
    Fertil Steril; 2011 May; 95(6):2125.e13-4. PubMed ID: 21292254
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database.
    Cho Y; Bea S; Bae JH; Kim DH; Lee JH; Shin JY
    Expert Opin Drug Saf; 2024 Aug; 23(8):1027-1033. PubMed ID: 38112005
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Oral Finasteride Presents With Sexual-Unrelated Withdrawal in Long-Term Treated Androgenic Alopecia in Men.
    Perez-Mora N; Velasco C; Bermüdez F
    Skinmed; 2015; 13(3):179-83. PubMed ID: 26380503
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss.
    Guo M; Heran B; Flannigan R; Kezouh A; Etminan M
    Pharmacotherapy; 2016 Nov; 36(11):1180-1184. PubMed ID: 27644029
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men.
    Walf AA; Kaurejo S; Frye CA
    Am J Mens Health; 2018 Jul; 12(4):900-906. PubMed ID: 29318957
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases.
    Wu M; Yu Q; Li Q
    Oncotarget; 2016 Dec; 7(50):82074-82084. PubMed ID: 27738338
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia.
    Courtney A; Triwongwarant D; Chim I; Eisman S; Sinclair R
    Expert Opin Pharmacother; 2023; 24(18):1919-1922. PubMed ID: 37942878
    [No Abstract]   [Full Text] [Related]  

  • 72. Post-finasteride syndrome - does it really exist?
    Maksym RB; Kajdy A; Rabijewski M
    Aging Male; 2019 Dec; 22(4):250-259. PubMed ID: 30651009
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study.
    Vañó-Galván S; Saceda-Corralo D; Moreno-Arrones OM; Rodrigues-Barata R; Morales C; Gil-Redondo R; Bernárdez-Guerra C; Hermosa-Gelbard Á; Jaén-Olasolo P
    Dermatol Ther; 2020 Jan; 33(1):e13182. PubMed ID: 31820540
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association Between 5-Alpha Reductase Inhibitor Use and The Risk of Depression: A Meta-Analysis.
    Deng T; Duan X; He Z; Zhao Z; Zeng G
    Urol J; 2020 Aug; 18(2):144-150. PubMed ID: 32869255
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Persistent sexual side effects of finasteride: could they be permanent?
    Canguven O; Talib RA
    J Sex Med; 2013 May; 10(5):1441. PubMed ID: 23421328
    [No Abstract]   [Full Text] [Related]  

  • 76. Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.
    Melcangi RC; Caruso D; Abbiati F; Giatti S; Calabrese D; Piazza F; Cavaletti G
    J Sex Med; 2013 Oct; 10(10):2598-603. PubMed ID: 23890183
    [TBL] [Abstract][Full Text] [Related]  

  • 77. What's wrong with chemoprevention of prostate cancer?
    Justman S
    Am J Bioeth; 2011 Dec; 11(12):21-5. PubMed ID: 22146025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome.
    Baas WR; Butcher MJ; Lwin A; Holland B; Herberts M; Clemons J; Delfino K; Althof S; Kohler TS; McVary KT
    Urology; 2018 Oct; 120():143-149. PubMed ID: 29960004
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of 5-alpha reductase inhibitors: new insights on benefits and harms.
    Lee JY; Cho KS
    Curr Opin Urol; 2018 May; 28(3):288-293. PubMed ID: 29528971
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia?
    Federman DG
    Mayo Clin Proc; 2006 Feb; 81(2):267; author reply 267-8. PubMed ID: 16471089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.